View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBRAIN Biotech 配当と自社株買い配当金 基準チェック /06BRAIN Biotech配当金を支払った記録がありません。主要情報n/a配当利回り-14.6%バイバック利回り総株主利回り-14.6%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.決済の安定と成長配当データの取得安定した配当: BNNDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BNNDの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場BRAIN Biotech 配当利回り対市場BNND 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BNND)n/a市場下位25% (GB)2.2%市場トップ25% (GB)5.6%業界平均 (Chemicals)3.7%アナリスト予想 (BNND) (最長3年)0%注目すべき配当: BNNDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BNNDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BNNDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BNNDが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/19 02:43終値2022/09/21 00:00収益2022/06/30年間収益2021/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BRAIN Biotech AG 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Yi-Dan WangDeutsche BankJan KochDeutsche BankJan KochDeutsche Bank5 その他のアナリストを表示
お知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026
お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.
お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025
お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025
お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025
お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025
お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024
お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024
お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024
お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.
お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023
お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.
お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.
Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.